{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:58:41Z","timestamp":1787165921637,"version":"build-2736575974"},"reference-count":29,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,1,19]]},"abstract":"<jats:p>Background: Anti-IgLON5 disease is a rare neurodegenerative tauopathy that displays heterogeneity in clinical spectrum, disease course, cerebrospinal fluid (CSF) findings, and variable response to immunotherapy. Sleep disorders, bulbar dysfunction, and gait abnormalities are common presenting symptoms, and conventional brain MRI scanning is often unrevealing. Objective: To provide a comprehensive overview of the literature and to assess the frequency of symptoms, MRI findings, and treatment response in patients with IgLON5 autoimmunity in the serum and CSF or restricted to serum. Methods: We examined a 65-year-old woman with bulbar-onset IgLON5 disease with serum-restricted antibodies, and we also performed a systematic review of all confirmed cases reported in the English literature. Results: We identified 93 patients, included our case. Clinical data were obtained in 58 subjects, in whom the most frequent symptoms were sleep-disordered breathing, dysphagia, parasomnias, dysarthria, limb or gait ataxia, stridor or vocal cord paresis, movement disorders, and postural instability. Distinct MRI alterations were identified in 12.5% of cases, as opposed to unspecific or unremarkable changes in the remaining patients. T2-hyperintense non-enhancing signal alterations involving the hypothalamus and the brainstem tegmentum were observed only in the present case. Inflammatory CSF was found in half of the cases and serum-restricted antibodies in 4 patients. Treatment with immunosuppressant or immunomodulatory drugs led to sustained clinical response in 19\/52 patients. Conclusion: Anti-IgLON5 autoimmunity should be considered in patients with sleep disorders, bulbar syndrome, autonomic involvement, and movement disorders, and high-field brain MRI can be of diagnostic help.<\/jats:p>","DOI":"10.3233\/jad-201105","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T10:24:42Z","timestamp":1608287082000},"page":"683-691","source":"Crossref","is-referenced-by-count":19,"title":["Hypothalamic-Bulbar MRI Hyperintensity in Anti-IgLON5 Disease with Serum-Restricted Antibodies: A Case Report and Systematic Review of Literature"],"prefix":"10.1177","volume":"79","author":[{"given":"Matteo","family":"Tagliapietra","sequence":"first","affiliation":[{"name":"Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Frasson","sequence":"additional","affiliation":[{"name":"Neurology Ward, Ospedale di Cittadella, Cittadella, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cardellini","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mariotto","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Zanusso","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Plebani","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Monaco","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-201105_ref1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical manifestations of the anti-IgLON5 disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-201105_ref2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: A case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-201105_ref3","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.3233\/JAD-201105_ref4","doi-asserted-by":"crossref","first-page":"zsz133","DOI":"10.1093\/sleep\/zsz133","article-title":"Characterization of the sleep disorder of anti-IgLON5 disease","volume":"42","author":"Gaig","year":"2019","journal-title":"Sleep"},{"key":"10.3233\/JAD-201105_ref5","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1212\/NXI.0000000000000605","article-title":"HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease","volume":"6","author":"Gaig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.3233\/JAD-201105_ref6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society Criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-201105_ref7","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.3233\/JAD-201105_ref8","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1212\/NXI.0000000000000485","article-title":"Subacute encephalitis with recovery in IgLON5 autoimmunity","volume":"5","author":"Ramanan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.3233\/JAD-201105_ref9","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3389\/fimmu.2018.02708","article-title":"Management of autoimmune encephalitis: An observational monocentric study of 38 patients","volume":"9","author":"Macher","year":"2018","journal-title":"Front Immunol"},{"key":"10.3233\/JAD-201105_ref10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.sleep.2019.11.1245","article-title":"Anti IgLON5 disease - first case report from India","volume":"67","author":"Bhatia","year":"2019","journal-title":"Sleep Med"},{"key":"10.3233\/JAD-201105_ref11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fneur.2018.00329","article-title":"IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes","volume":"9","author":"Montagna","year":"2018","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-201105_ref12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/mdc3.12679","article-title":"Anti-IgLON5 disease responsive to immunotherapy: A case report with an abnormal MRI","volume":"5","author":"Moreno-Est\u00e9banez","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JAD-201105_ref13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamaneurol.2019.3638","article-title":"Distinctive magnetic resonance imaging findings in IgLON5 antibody disease","volume":"77","author":"Chen","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-201105_ref14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jneuroim.2014.08.027","article-title":"Autoantibodies against IgLON5: Two new cases","volume":"275","author":"Bahtz","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.3233\/JAD-201105_ref15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/mdc3.12407","article-title":"Gaze palsy, sleep and gait disorder, as well as Tako-Tsubo syndrome in a patient with IgLON5 antibodies","volume":"4","author":"Montojo","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JAD-201105_ref16","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1212\/NXI.0000000000000136","article-title":"Sleep disorder, chorea, and dementia associated with IgLON5 antibodies","volume":"2","author":"Simabukuro","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.3233\/JAD-201105_ref17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-170189","article-title":"Microglial and neuronal TDP-43 pathology in anti-IgLON5-related tauopathy","volume":"59","author":"Cagnin","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-201105_ref18","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1212\/NXI.0000000000000577","article-title":"Immunotherapy improves sleep and cognitive impairment in anti-IgLON5 encephalopathy","volume":"6","author":"Brunetti","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.3233\/JAD-201105_ref19","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1212\/NXI.0000000000000651","article-title":"Anti-IGLON5 disease: A new case without neuropathologic evidence of brainstem tauopathy","volume":"7","author":"Erro","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.3233\/JAD-201105_ref20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00401-016-1591-8","article-title":"Neuropathological criteria of anti-IgLON5-related tauopathy","volume":"132","author":"Gelpi","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-201105_ref21","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1212\/NXI.0000000000000302","article-title":"Isolated dysphagia as initial sign of anti-IgLON5 syndrome","volume":"4","author":"Schr\u00f6der","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.3233\/JAD-201105_ref22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.anl.2007.03.006","article-title":"Paradoxical vocal cord motion: A review focused on multiple system atrophy","volume":"34","author":"Shiba","year":"2007","journal-title":"Auris Nasus Larynx"},{"key":"10.3233\/JAD-201105_ref23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ar.1092370111","article-title":"Nucleus ambiguus of the rabbit: Cytoarchitectural subdivision and myotopical and neurotopic representations","volume":"237","author":"Kitamura","year":"1993","journal-title":"Anat Rec"},{"key":"10.3233\/JAD-201105_ref24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ar.22643","article-title":"Somatotopy of the neurons innervating the cricothyroid, posterior cricoarytenoid, and thyroarytenoid muscles of the rat\u2019s larynx","volume":"296","author":"Hern\u00e1ndez-Morato","year":"2013","journal-title":"Anat Rec"},{"key":"10.3233\/JAD-201105_ref25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/mdc3.12957","article-title":"Corticobasal syndrome in a patient with anti-IgLON5 antibodies","volume":"7","author":"Fuseya","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JAD-201105_ref26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mds.26608","article-title":"Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies","volume":"31","author":"Br\u00fcggemann","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-201105_ref27","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-201105_ref28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","article-title":"Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome","volume":"13","author":"Sabater","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-201105_ref29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/acn3.561","article-title":"Elevated LGI1-IgG CSF index predicts worse neurological outcome","volume":"5","author":"Gadoth","year":"2018","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-201105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:39Z","timestamp":1777370679000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-201105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":29,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-201105","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]}}}